Great Lakes Advisors LLC Sells 2,714 Shares of Becton, Dickinson and Company $BDX

Great Lakes Advisors LLC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.2% in the third quarter, HoldingsChannel reports. The fund owned 218,800 shares of the medical instruments supplier’s stock after selling 2,714 shares during the period. Great Lakes Advisors LLC’s holdings in Becton, Dickinson and Company were worth $40,954,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after buying an additional 4,305,947 shares during the period. Norges Bank bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $653,377,000. First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after acquiring an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Becton, Dickinson and Company by 24.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after purchasing an additional 1,670,590 shares during the last quarter. Finally, Laurel Wealth Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 16,974.4% in the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock worth $272,049,000 after purchasing an additional 1,570,136 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 2,680 shares of company stock worth $539,848. 0.40% of the stock is currently owned by company insiders.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board set the record date (Feb 5) and distribution/close date (Feb 9) for the spin-off of BD’s Biosciences & Diagnostic Solutions business — a material corporate action that can unlock value separation and clarify BD’s portfolio for investors. Read More.
• Positive Sentiment: Waters Corporation shareholders approved the combination with BD’s Biosciences & Diagnostic Solutions unit, clearing a regulatory/transactional step that advances the planned deal underpinning the spin-off strategy. Read More.
• Positive Sentiment: Board declared a $1.05 quarterly dividend (payable Mar 31; record/ex-div Mar 10), supporting income investors and signaling cash-return discipline. Read More.
• Positive Sentiment: Authorized an additional $10 million in share repurchases and reported ~$250M repurchased YTD — a constructive buyback signal although the new authorization is small relative to BD’s ~$57B market cap. Read More.
• Positive Sentiment: Launched BD Research Cloud 7.0 featuring AI-powered tools for flow cytometry — product innovation that may support recurring software/service revenue and strengthen diagnostics positioning. Read More.
• Positive Sentiment: Partnered with Envetec to demonstrate closed-loop recycling for laboratory plastics — a sustainability/ESG initiative that can reduce waste and appeal to healthcare customers focused on lifecycle impact. Read More.
• Neutral Sentiment: BD will release fiscal Q1 results and host a management webcast — an upcoming catalyst that could drive short-term volatility depending on revenue, margins, and spin-off-related commentary. Read More.
• Neutral Sentiment: Analyst and media pieces reiterate BD as a long-term value/defensive healthcare name vs. peers — supportive for sentiment but not an immediate price mover. Read More.
• Negative Sentiment: Insider sale: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26 — a very small reduction (0.45% of his holding) unlikely to change fundamentals but sometimes cited by short-term traders. Read More.

Becton, Dickinson and Company Stock Down 0.8%

NYSE:BDX opened at $201.81 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The firm’s 50-day moving average price is $198.08 and its 200-day moving average price is $190.98. The company has a market capitalization of $57.50 billion, a PE ratio of 34.62, a P/E/G ratio of 2.25 and a beta of 0.23. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. During the same quarter in the prior year, the company earned $3.81 earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has approved a stock repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Four research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $209.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.